Company interests and priorities



Seeking opportunities to enhance cancer treatments by modulating the microbiome

Microviable Therapeutics is a biotech company at preclinical stage developing novel biological drugs based on the microbiota to address unmet challenges in human diseases.



R&D challenges and priority areas:

- Modulate the microbiome to enhance cancer treatments and or reduce the toxicity of cancer treatments
- Use microbiome-derived biotherapeutic products for the above mentioned applications

Specific opportunities and approaches of interest:

Must be related to oncology and autoimmune disorders

Stages of development preferred:

Pre-clinical

Types of collaboration preferred:

• Research and development with university partner having expertise in a complimentary area

SUBMIT OPPORTUNITIES